Natural Phenomenon or Process
FibroGen to Shrink US Workforce by 75% Following More Late-Stage Fails
FibroGen, workforce reduction, pamrevlumab, clinical trials, biotech layoffs, pancreatic cancer drug
Fierce Biotech Layoff Tracker 2024: GlycoMimetics Cuts 80% of Company; Anokion Undergoes Cuts
Biotech Layoffs, GlycoMimetics, Anokion, Pharmaceutical Industry, Job Cuts, Cost Reduction
RAPT Therapeutics Announces Significant Workforce Reduction Following Clinical Hold on Zelnecirnon Trials
RAPT Therapeutics, zelnecirnon, clinical hold, workforce reduction, FDA, clinical trials, atopic dermatitis, asthma, oncology, CCR4 agonist
Ginkgo Bioworks to Lay Off Up to 400 Employees Amid Cost-Cutting Measures
Ginkgo Bioworks, layoffs, cost-cutting, biosecurity, cell programming, workforce reduction
Silence’s siRNA therapy maintains Lp(a) lowering in cardiovascular study
Lp(a ), RNA, Small Interfering, Cardiovascular Diseases
Annexon Shares Soar as ANX005 Meets Primary Endpoint in Phase 3 Trial for Guillain-Barré Syndrome
Annexon, ANX005, Guillain-Barré Syndrome, Phase 3 Trial, Primary Endpoint, Disability Reduction, Share Price Surge
Biohaven’s Phase I Data for Lead Protein Degrader Falls Short of Investor Expectations ###
Biohaven, BHV-1300, Protein degrader, IgG reduction, Phase I study, Investor expectations, Autoimmune disorders, Rheumatoid arthritis, Myasthenia gravis
AstraZeneca’s Oral PCSK9 Inhibitor AZD0780 Demonstrates Significant LDL-C Reduction in Phase 1 Trial
PCSK9 inhibitor, AZD0780, AstraZeneca, cholesterol reduction, phase 1 trial, statin therapy, hypercholesterolemia, cardiovascular disease
Minimal Weight Reduction Observed with Low Doses of New Zealand’s GLP-1/GLP-2 Agonist
New Zealand, GLP-1/GLP-2 agonist, weight reduction, lowest doses, minimal effect.
Exscientia Streamlines Operations, Prioritizes AI-Driven Drug Discovery
Exscientia, AI-generated pipeline, drug discovery, staff reduction, operational efficiency, biotechnology, pharmaceutical industry